Pharmacologic agents capable of increasing kinase function would be useful for treating diseases associated with reduced kinase activity, such as inherited forms of Parkinson's disease. In this issue, Hertz et al. report an innovative approach for activating the Parkinson's-associated kinase PINK1 in cells with an ATP-derived neo-substrate.
Small molecules that modulate the activity of protein targets are powerful tools for probing biology and can serve as starting points for developing life-saving therapeutics. In particular, compounds that inhibit protein kinase activity have attracted considerable attention because they have the potential to treat conditions characterized by rampant kinase activation, such as cancer and inflammatory disease ( Figure 1A ). Small-molecule inhibitors now exist for many human kinases, and as of this writing, there are 14 FDA-approved kinase inhibitor drugs. In contrast, there are very few examples of small molecules that can activate kinases, even though such compounds could prove useful as drugs to treat diseases linked to impaired kinase function, such as neurodegenerative diseases and diabetes. In this issue of Cell, Hertz et al. (2013) describe an exciting approach for pharmacologically activating kinase function-namely, providing a kinase with a ''bumped'' ATP substrate (neo-substrate) that is processed with higher catalytic efficiency than its native substrate ( Figure 1B) .
Why are there so few small-molecule kinase activators? This is likely because the molecular constraints required for kinase activation are arguably more stringent than those imposed upon inhibition. A small-molecule activator needs to exert its effect while preserving the multiple essential steps of catalysis, such as substrate binding, transition-state stabilization, and product release. An inhibitor need only interfere with one of these processes to shut down the catalytic cycle. Most of the known examples of smallmolecule kinase activators rely on binding to an allosteric site in order to shift the conformational equilibrium and favor the active over inactive kinase conformation (Simpson et al., 2009) . Although allosteric regulation can be effective, it is only feasible for kinases that possess a wellcharacterized allosteric site. Hertz et al. (2013) apply their strategy in a therapeutically relevant context to increase the catalytic activity of PTENinduced kinase 1 (PINK1), a mitochondrial kinase in which loss-of-function mutations have been linked to the development of early-onset familial Parkinson's disease (PD) (Schapira, 2008) . PD, characterized by loss of the dopaminergic neurons in the substantia nigra, is the second most common neurodegenerative disease, affecting about 1% of those over 60 years of age in industrialized countries and affecting up to 4% of those older than 80 years (de Lau and Breteler, 2006) . PD is primarily an idiopathic disease, and the standard treatment remains L-DOPA (the biosynthetic precursor to dopamine), which treats the symptoms rather than the causes of the disease.
Mitochondrial dysfunction has long been associated with parkinsonism, and the identification of mutations in mitochondrial proteins has pointed to a possible genetic link to the disease. Defects in two mitochondrial proteins-PINK1, a Ser/Thr kinase, and PRK2 (Parkin), an E3 ubiquitin ligase-have been linked to familial PD. PINK1 and Parkin are essential players in the elimination of damaged mitochondria, a process known as mitophagy. Upon induction of mitochondrial damage, Parkin is rapidly recruited from the cytosol to damaged (but not to healthy) mitochondria, where it ubiquitinates its substrates, thereby stimulating mitochondrial degradation (Narendra et al., 2010) . Selective recruitment of Parkin requires PINK1, which promotes Parkin binding through phosphorylation of Mfn2, a recently identified mitochondrial Parkin receptor (Chen and Dorn, 2013) . Consistent with a neuroprotective role of PINK1 kinase activity, the most deleterious clinically relevant mutations in PINK1 occur in the kinase domain and inhibit catalysis (Song et al., 2013) , suggesting that activation of PINK1 mutants with reduced kinase activity may constitute an effective therapeutic approach in certain forms of PD. Hertz et al. (2013) investigate strategies to increase PINK1 kinase activity with pharmacologic agents. Although there is no available structural information on PINK1 (which precludes the rational design of an allosteric activator), sequence analysis of the kinase domain enables the authors to identify regions of divergence from the canonical kinase fold, suggesting that PINK1 could have altered nucleotide binding specificity. In addition, their own widely recognized studies have shown that kinases with a single mutation at the ''gatekeeper'' residue can accept N 6 -modified ATP analogs (the ''bump-andhole'' strategy for engineering analog-sensitive kinase alleles). Motivated by these findings, the authors identify the ATP analog N 6 -furfuryl ATP (kinetin triphosphate, KTP) ( Figure 1B ) as a substrate that PINK1 accepts with higher catalytic efficiency (increased V max and lower K m ) than its native substrate, ATP. This would be a nice biochemical finding on its own, but its greater utility would be limited because KTP, like other nucleoside triphosphates, is not expected to be cell permeable or stable.
Remarkably, the authors find that KTP can be generated intracellularly by feeding cells kinetin (N 6 -furfuryl adenine), which is enzymatically ribosylated and phosphorylated to give the nucleoside triphosphate ( Figure 1B ). When combined with oxidative stress (in the form of chemically induced mitochondrial depolarization), kinetin treatment of HeLa cells transfected with the catalytically deficient PINK1 G309D mutant or neuronal cells containing wild-type PINK1 results in rescued mitochondrial Parkin recruitment, reduced mitochondrial motility, and antiapoptotic effects that are consistent with increased PINK1 activity, thereby validating this neo-substrate strategy for PINK1 activation. Although familial PD associated with inactivating mutations in PINK1 is rare, treatment options for PD are limited, and this study shows that pharmacologic PINK1 activation with kinetin may constitute a viable therapeutic route in certain instances of the disease. Unfortunately, Parkin lies downstream of PINK1 in the mitophagic pathway and is more frequently mutated in PD (Schapira, 2008) ; it is unlikely that PINK1 activation will be therapeutically effective in treating PD caused by Parkin dysfunction.
Importantly, this study brings to light the unrealized therapeutic potential of drugging kinases with neo-substrate small-molecule activators rather than inhibitors. Adenine-like molecules, such as the pyrazolopyrimidine-based compounds, can act as potent and specific kinase inhibitors. It is possible that the vast available knowledge for such specific kinase binders will aid in the identification of other adenine-related compounds that can be intracellularly converted into nucleoside triphosphates and used as specific neo-substrate activators for kinases in general.
Moreover, ATPases constitute one of the larger superfamilies in the human proteome, but we lack cell-permeable small-molecule activators for almost all of these proteins. Because ATP hydrolysis is a common feature shared by these enzymes, the neo-substrate strategy outlined by Hertz et al. (2013) could present a broadly applicable approach to activating ATPase function. In particular, the AAA+ (ATPases associated with diverse cellular activities) family represents a large class of ATP-hydrolyzing proteins whose loss of function has been implicated in human diseases such as neuronal dysfunctions, bone disease, and ciliopathy (White and Lauring, 2007) (Figure 1C ). Although smallmolecule modulation of AAA+ proteins is largely unexplored, ATP-competitive inhibitors for dynein and p97/VCP have been reported recently (Chou et al., 2011; Firestone et al., 2012) . Characterizing these compounds will shed light on the molecular recognition parameters for binding the AAA+ ATP pocket and may aid in the design of neo-substrate activators for this protein family.
There will be several steps before kinetin or related compounds can be developed as therapeutic agents. The findings reported by Hertz et al. (2013) represent an exciting first step and establish a new paradigm for using chemicals to control enzyme function in cellular contexts. (Hertz et al., 2013) describe an approach for increasing PINK1 kinase activity with an ATP-derived neo-substrate, KTP, which can be generated intracellularly by feeding cells kinetin. Impairment of PINK1 kinase activity leads to defects in the mitochondrial elimination pathway and has been linked to early-onset familial PD. (C) The neo-substrate strategy for ATPase activation presents a unique opportunity to increase the activity of other ATPases whose loss of function has been linked to human disease, such as members of the AAA+ family.
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Based on a massive transcription factor location analysis within a single cell type, in this issue Yan et al. find that the great majority of occupancies occur within dense clusters of up to 100 factors that almost invariably contain cohesins. Retention of cohesins at cluster sites during mitosis raises the possibility that they contribute to transcriptional memory during the cell cycle.
Transcriptional regulators function combinatorially to control eukaryotic gene expression at the right place, time, and level. Transcription-factor-binding sites cluster at regulatory elements that can be promoter proximal but also be located up to hundreds of kilobases away. Juxtaposition of cis elements might confer synergy in binding to chromatin and in the recruitment of coregulatory molecules. Most known enhancer elements bind tissue-and gene-specific factors in combination with widely expressed DNA-binding proteins.
In this issue of Cell, Yan et al. (2013) take the analysis of transcription factor occupancy at enhancers to a new level by analyzing in a single cell type over 100 transcription factors by ChIP-seq (chromatin immunoprecipitation followed by second-generation sequencing), including DNA-binding and nonbinding coregulators. The number of factors examined exceeds the total number of transcription factors published previously by the ENCODE project (Gerstein et al., 2012) .
Transcription-factor-binding sites vary in number from 300 to 45,000 but, notably, occur in clusters of up to 100 transcription factors confined on average to less than 2 kb in size. Cluster sizes correlate with gene expression and enhancer chromatin marks as one might expect but, surprisingly, clusters include factors that share few functional GO annotations. Although clusters of transcription factor binding have been observed in multiple recent studies (socalled high occupancy or HOT regions; MacArthur et al., 2009; Yip et al., 2012) , the sheer number of transcription factors examined in the present study reveals a far greater degree of transcription factor clustering than previously observed.
Yan et al. point out that a substantial number of factors must be examined to observe the clusters, and one would expect that further mapping of additional factors will show how commonly clusters capture the majority of binding. The authors also find that the vast majority of clusters containing at least 20 transcription factors are marked by the presence of cohesin. Previous experiments in Drosophila and mice also found that nearly all cis-regulatory modules are bound by cohesin and/or its loading factors (Kagey et al., 2010; Schaaf et al., 2013) , but recent studies of co-occupancy of large numbers of factors in human cells do not find cohesin as part of almost all clusters (Gerstein et al., 2012; Yip et al., 2012) . Again, further mapping of the locations of larger numbers of factors in diverse species and cell types should resolve this apparent discrepancy. Importantly, each study defined clusters in a distinct way and employed different methods of analysis. Future work should reveal which conclusions are robust to the different methodological approaches.
Cohesins in combination with mediator and/or CTCF are thought to aid in forming
